Probi appoints Glenn Gibson, Maria Rescigno and Henrik Vestergaard to Scientific Advisory Board
Probi renews its Scientific Advisory Board to further strengthen its Probiotic business by increasing the understanding of the microbiome and its impact on health.
Glenn Gibson is Professor of Food Microbiology and Head of Food Microbial Sciences at the University of Reading, UK. Glenn´s current research includes acute and chronic gut disease, autism, obesity, novel prebiotics, and human metabonomics. Additional areas of expertise include probiotics, gastroenteritis in sports, metabolic syndrome and gut flora development with age.
Prof. Maria Rescigno, is Director of the Dendritic Cell Biology and Immunotherapy Unit at the European Institute of Oncology in Milan, Italy. Her major field of interest is the mucosal immune system, in particular antigen-presentation by dendritic cells and bacterial handling in the gut. Her line of research includes studies of host-microbe interactions at mucosal surfaces.
Henrik Vestergaard, is Associate Professor at the Novo Nordic Foundation Center for Basic Metabolic Research in Copenhagen, Denmark. As a specialist in internal medicine and endocrinology, Henrik brings clinical experience and expertise within the area of metabolic diseases. His current research includes genetics of cardiometabolic diseases, gene-environment interaction, glycemic control, prediabetes and type 2 diabetes.
“Our new members are highly respected in their respective fields of research,” says Peter Nählstedt, Chief Executive Officer of Probi. “We are very pleased to welcome them all to our Scientific Advisory Board and look forward to fruitful discussions on Probi scientific development. We also wish to thank resigning members for their valuable contributions over the years.”
Additional members of Probi Scientific Advisory Board, are:
Hans Wigzell, Professor of Immunology at the Department of microbiology, tumor and cellbiology of Karolinska Institute, Stockholm, Sweden.
Lars Gatenbeck, MD, PhD, Founder and Chairman at Life Equity Group, Stockholm, Sweden.
Jan Nilsson, Professor of Cardiovascular Experimental Research at Lund University , Lund, Sweden.
FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: peter.nahlstedt@probi.se
Gun-Britt Fransson, Vice President Research & Development, Probi, tel +46 46 286 89 74 or mobile +46 705 95 73 27, e-mail: gun-britt.fransson@probi.se
ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 30 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. Probi had sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm, Small-cap. Probi has approximately 4,000 shareholders. Read more on www.probi.se.
Tags:
